![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MEDICINOVA INITIATES PHASE II MS DRUG TRIAL
MEDICINOVA INITIATES PHASE II MS DRUG TRIAL
August 2, 2005
MediciNova has begun enrolling patients in a Phase II clinical study with MN-166
for the treatment of multiple sclerosis (MS), an inflammatory demyelinating
disease of the central nervous system. MN-166 is an orally administered drug
with a novel mechanism of action that includes the inhibition of phosphodiesterase
IV.
MN-166 has a proven record of safety and tolerability, and has the major advantage
of oral dosing. In small, open-label studies in patients with relapsing-remitting
MS, MN-166 produced encouraging activity. The Phase II study is being conducted
in nine countries in Eastern Europe, and will compare two oral doses of MN-166
to placebo in 300 patients with relapsing-remitting MS.
The study will measure reduction in MS lesions in the brain as detected by magnetic
resonance imaging, reductions in annualized relapse rates and functional status
as determined by the Expanded Disability Status Scale.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct